<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> efficacy of P-4055, a 5'-<z:chebi fb="0" ids="27997">elaidic acid</z:chebi> (C18:1, <z:chebi fb="2" ids="27208">unsaturated fatty acid</z:chebi>) <z:chebi fb="21" ids="35701">ester</z:chebi> of <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, a <z:chebi fb="0" ids="33838">nucleoside</z:chebi> <z:chebi fb="0" ids="35221">antimetabolite</z:chebi> frequently used in the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, was examined in several in vivo models for human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In initial dose-finding studies in <z:mp ids='MP_0003815'>nude</z:mp> mice, the efficacy of P-4055 was highest when using schedules with repeated daily doses </plain></SENT>
<SENT sid="2" pm="."><plain>In a Raji Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> leptomeningeal <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> model in <z:mp ids='MP_0003815'>nude</z:mp> rats, the control <z:chebi fb="0" ids="28680">cytarabine</z:chebi>- and saline-treated animals (five in each group) had a mean survival time of 13.2 days, whereas treatment with P-4055 resulted in three of five long-time survivors (&gt;70 days) </plain></SENT>
<SENT sid="3" pm="."><plain>In a systemic Raji <z:hpo ids='HP_0001909'>leukemia</z:hpo> model in <z:mp ids='MP_0003815'>nude</z:mp> mice, 8 of 10 of the P-4055-treated animals survived (&gt;80 days), compared with none of the <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-treated animals (mean survival time, 34.2 days) </plain></SENT>
<SENT sid="4" pm="."><plain>In s.c. <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e>, the effects of maximum tolerated doses of P-4055 and <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (three <z:hpo ids='HP_0002861'>melanomas</z:hpo>, one <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp>, one <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, and two <z:hpo ids='HP_0002669'>osteogenic sarcomas</z:hpo>) were investigated </plain></SENT>
<SENT sid="5" pm="."><plain>P-4055 induced partial or complete <z:mp ids='MP_0010537'>tumor regression</z:mp> of the <z:mp ids='MP_0008714'>lung carcinoma</z:mp>, as well as of <z:hpo ids='HP_0000001'>all</z:hpo> three <z:hpo ids='HP_0002861'>malignant melanomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In two of the <z:hpo ids='HP_0002861'>melanomas</z:hpo> the activity was highly superior to that of <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and both P-4055 and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> were, in general, more effective than several clinically established drugs previously tested in the same <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="7" pm="."><plain>In in vitro studies, inhibitors of <z:chebi fb="0" ids="33838">nucleoside</z:chebi> carrier-dependent transport, nitrobenzylmercaptopurine riboside and dipyridamol, reduced strongly the cellular sensitivity to <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, but not to P-4055, indicating that P-4055 uses an alternative/additional mechanism of internalization into the cell compared with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The results explain, at least in part, the observed differences between the two compounds in in vivo efficacy, and together the data strongly support the evaluation of P-4055 in clinical studies </plain></SENT>
</text></document>